Back to News
Market Impact: 0.25
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
A 200 mg low dose of budoprutug demonstrated B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data. Additional results from the PrisMN Phase 2 study are anticipated in 2027.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Trump set to announce plan by Audi to build a U.S. factory in Georgia, source says
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Instacart reportedly discussed selling itself with DoorDash and Uber
- Biotech stocks are surging. How investors can play the new drug innovation boom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)